COMMUNIQUÉS West-GlobeNewswire

ZoomRx Launches Marketing Asset Testing (MAT) on Sagan Agents, Bringing Continuous, Channel-Specific Asset Testing to Pharma Brand Teams
13/10/2026
A new AI-powered application replaces the yearly messaging or concept testing study with cost-effective, iterative tests that optimize every marketing asset using synthetic and real HCPs, delivering results in days [...]
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
13/10/2026
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These [...]
Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis
13/10/2026
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage [...]
Opus Genetics to Present at the Chardan Annual Healthcare Conference
13/10/2026
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Sironax Advances Enrollment in Phase 2 FORGE-LM Obesity Trial of NAMPT Activator SIR4156
13/10/2026
Evaluating first-in-class asset to potentially address current obesity treatment deficiencies by promoting weight loss and preserving lean body mass WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Sironax, a global [...]
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
13/10/2026
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% [...]
The Mindful CRNA Bootcamp Trains Nurses to Handle the Pressure of CRNA School
13/10/2026
Starting October 21, the live program helps nurses build the inner capacity that CRNA school demands. Founder Amanda Kay, MSN, CRNA, will close it with news about the platform's next chapter. CHICAGO, Oct. 13, 2026 ( [...]
TaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026
13/10/2026
Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV TAIPEI, Taiwan, Oct. 13, 2026 ( [...]
Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio
13/10/2026
Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Envisagenics, Inc. , an AI-driven [...]
Rgenta Therapeutics Announces RGT-61159 Poster Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
13/10/2026
WOBURN, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
De l’océan au bien-être animal : Acadian lance la technologie d’alimentation optimisée Tasco®, conçue pour renforcer la résilience et la productivité
13/10/2026
DARTMOUTH, Nouvelle-Écosse, 13 oct. 2026 (GLOBE NEWSWIRE) -- Acadian Animal Wellness a annoncé aujourd’hui le lancement mondial de la technologie d’alimentation optimisée Tasco® destinée aux produits d’alimentation [...]
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
13/10/2026
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic [...]
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
13/10/2026
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
MBX Biosciences to Participate in Upcoming November Investor Conferences
13/10/2026
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
13/10/2026
SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced [...]
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
13/10/2026
The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa [...]
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
13/10/2026
Third drug candidate from Tenvie’s product engine to enter clinical development in 2026 TNV313 joins TNV262 to give Tenvie two clinical-stage, fully CNS-penetrant NLRP3 inhibitors, enabling parallel development across [...]
Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026
13/10/2026
First clinical data for OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid tumors to current therapies, including [...]
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
13/10/2026
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in- [...]

Pages